Xanthone Derivatives Enhance the Therapeutic Potential of Neomycin against Polymicrobial Gram-Negative Bacterial Infections

Sayed Mohamad Safwan,Neeraj Kumar,Devashish Mehta,Mohit Singh,Varsha Saini,Nishant Pandey,Steffi Khatol,Shalini Batheja,Jitender Singh,Preeti Walia,Avinash Bajaj
DOI: https://doi.org/10.1021/acsinfecdis.3c00471
IF: 5.578
2024-01-31
ACS Infectious Diseases
Abstract:Gram-negative bacterial infections are difficult to manage as many antibiotics are ineffective owing to the presence of impermeable bacterial membranes. Polymicrobial infections pose a serious threat due to the inadequate efficacy of available antibiotics, thereby necessitating the administration of antibiotics at higher doses. Antibiotic adjuvants have emerged as a boon as they can augment the therapeutic potential of available antibiotics. However, the toxicity profile of antibiotic adjuvants is a major hurdle in clinical translation. Here, we report the design, synthesis, and biological activities of xanthone-derived molecules as potential antibiotic adjuvants. Our SAR studies witnessed that the <i>p</i>-dimethylamino pyridine-derivative of xanthone (<b>X8</b>) enhances the efficacy of neomycin (NEO) against <i>Escherichia coli</i> and <i>Pseudomonas aeruginosa</i> and causes a synergistic antimicrobial effect without any toxicity against mammalian cells. Biochemical studies suggest that the combination of <b>X8</b> and NEO, apart from inhibiting protein synthesis, enhances the membrane permeability by binding to lipopolysaccharide. Notably, the combination of <b>X8</b> and NEO can disrupt the monomicrobial and polymicrobial biofilms and show promising therapeutic potential against a murine wound infection model. Collectively, our results unveil the combination of <b>X8</b> and NEO as a suitable adjuvant therapy for the inhibition of the Gram-negative bacterial infections.
chemistry, medicinal,infectious diseases
What problem does this paper attempt to address?